Inhibition of the Rho / MRTF pathway improves the response of BRAF ‐resistant melanoma to PD1 / PDL1 blockade

Documenti analoghi

• PD‐1 blockade treatment in melanoma: Mechanism of response and tumor‐intrinsic resistance
  di: Tong Wang, et al.
  Pubblicazione: (2024)
• Adjuvant treatment with anti‐ PD ‐1 in acral melanoma: A nationwide study
  di: Manja Bloem, et al.
  Pubblicazione: (2024)
• Tumor eradication by triplet therapy with BRAF inhibitor, TLR 7 agonist, and PD‐1 antibody for BRAF‐mutated melanoma
  di: Kenta Nakamura, et al.
  Pubblicazione: (2024)
• A prediction model for response to immune checkpoint inhibition in advanced melanoma
  di: Isabella A. J. van Duin, et al.
  Pubblicazione: (2024)
• The risk of treatment‐related toxicities with PD‐1/PD‐L1 inhibitors in patients with lung cancer
  di: Hao Hu, et al.
  Pubblicazione: (2024)